Drug Profile
HB 001
Alternative Names: HB-001Latest Information Update: 08 Apr 2022
Price :
$50
*
At a glance
- Originator Huabo Biopharm
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Membrane protein inhibitors; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Apr 2022 Discontinued for Solid tumours in China (unspecified route)
- 28 Feb 2022 No recent reports of development identified for research development in Solid-tumours in China
- 16 Jan 2018 Huabo Biopharm has patent for HB 001 (Huabo Biopharm website, January 2018)